Advertisement

 

 

Apremilast for a psoriasis patient with HIV and hepatitis C.

Apremilast for a psoriasis patient with HIV and hepatitis C.
Author Information (click to view)

Reddy SP, Shah VV, Wu JJ,


Reddy SP, Shah VV, Wu JJ, (click to view)

Reddy SP, Shah VV, Wu JJ,

Advertisement

Journal of the European Academy of Dermatology and Venereology : JEADV 2017 04 27() doi 10.1111/jdv.14301

Abstract

A 46-year old male with HIV, hepatitis C, and moderate psoriasis was resistant to starting ultra violet B phototherapy due to scheduling issues. The patient had 8% body surface area (BSA) affected on the dorsal hands, elbows, and legs, did not have associated psoriatic arthritis, and had not tried any systemic therapy in the past. He was initiated on an apremilast starter pack (dosages titrated up from 10 mg to 30 mg over the course of one week) and maintained on 30 mg twice a day after one week. This article is protected by copyright. All rights reserved.

Submit a Comment

Your email address will not be published. Required fields are marked *

five × four =

[ HIDE/SHOW ]